Bard PowerPort lawsuit: implantable port device failure claims

Understanding the Bard PowerPort device and its intended use

The Bard PowerPort is an implantable port catheter system manufactured by C.R. Bard, Inc., now a subsidiary of Becton, Dickinson and Company (BD). These devices are surgically placed beneath the skin, typically in the chest area, to provide long-term venous access for patients requiring repeated intravenous treatments. The PowerPort system consists of a small titanium or plastic reservoir (the port) connected to a thin, flexible catheter that threads into a large central vein, usually the superior vena cava.

Implantable port devices like the Bard PowerPort are most commonly used in oncology settings, where cancer patients undergoing chemotherapy need reliable venous access over months or years of treatment. The device eliminates the need for repeated peripheral IV insertions, reducing patient discomfort and the risk of peripheral vein damage from caustic chemotherapy agents. Beyond oncology, PowerPort devices are used for patients requiring long-term antibiotic therapy, total parenteral nutrition, frequent blood transfusions, and other repeated intravenous treatments.

What distinguishes the Bard PowerPort from standard implantable ports is its designation as a "power-injectable" device, meaning it is designed to withstand the higher pressures used during contrast-enhanced CT scans. This feature was marketed as a significant advantage, allowing patients to receive both chemotherapy and diagnostic imaging through a single device. However, this very design feature has come under scrutiny as a contributing factor to the device failures that form the basis of current litigation.

The Bard PowerPort litigation centers on a pattern of catastrophic device failures — catheter fractures, migration to the heart and lungs, thrombosis, and infection — that plaintiffs allege stem from fundamental design and manufacturing defects.

The scope of Bard PowerPort device failures

The Bard PowerPort litigation centers on a pattern of catastrophic device failures that have caused severe injuries and, in some cases, death. These failures are not isolated incidents but rather systemic problems that plaintiffs allege stem from fundamental design and manufacturing defects.

Catheter fracture and breakage

The most commonly reported failure mode involves fracture of the catheter component. The catheter, a thin polyurethane or silicone tube, can develop stress fractures at the point where it connects to the port body or where it passes between the clavicle and first rib (a phenomenon known as "pinch-off syndrome"). When the catheter fractures, the distal fragment can embolize — breaking free and migrating through the venous system to the heart or lungs.

Catheter migration to heart and lungs

When a fractured catheter fragment migrates, it can lodge in the right atrium, right ventricle, or pulmonary arteries. This creates life-threatening emergencies including cardiac arrhythmia, cardiac perforation, cardiac tamponade, and pulmonary embolism. Retrieval of migrated catheter fragments typically requires an interventional radiology procedure or open-heart surgery, depending on the location and orientation of the fragment.

Thrombosis and blood clot formation

Bard PowerPort devices have been linked to an elevated risk of deep vein thrombosis (DVT) and catheter-related thrombosis. The presence of the catheter in the central venous system can trigger clot formation, particularly when the catheter tip is improperly positioned or when the device surface promotes platelet adhesion. These clots can result in pulmonary embolism, superior vena cava syndrome, or post-thrombotic syndrome with chronic disability.

Infection and sepsis

Port-related infections represent another significant category of injuries. Bacterial colonization of the device can lead to localized pocket infections, bloodstream infections (bacteremia), sepsis, and endocarditis. Cancer patients, whose immune systems are already compromised by their disease and chemotherapy, are particularly vulnerable to device-related infections that can become life-threatening.

The science behind Bard PowerPort design defects

Central to the Bard PowerPort litigation are allegations of specific design defects that render the device unreasonably dangerous. Attorneys building these cases should understand the technical and material science issues that experts rely upon to establish defect.

Barium sulfate degradation

A critical defect allegation involves the use of barium sulfate as a radiopaque filler in the catheter material. Barium sulfate is added to the polyurethane catheter so that it can be visualized on X-ray imaging. However, plaintiff experts contend that barium sulfate particles create stress concentration points within the polymer matrix. Over time, body fluids penetrate these micro-defects, causing hydrolytic degradation that weakens the catheter wall. This degradation is accelerated by the alkaline pH of blood and the mechanical stresses of daily movement, breathing, and the cardiac cycle.

Polyurethane material vulnerabilities

The polyurethane used in Bard PowerPort catheters is subject to several well-documented degradation mechanisms in vivo. Environmental stress cracking (ESC), metal-ion oxidation (MIO), and calcification can all compromise the structural integrity of the catheter over time. Plaintiffs allege that Bard knew or should have known about these degradation pathways and that alternative catheter materials, such as silicone, offered superior biostability.

Connector and hub design flaws

The junction between the catheter and the port body represents a critical stress point. Plaintiffs allege that the connector design in certain PowerPort models does not adequately distribute mechanical stress, leading to premature fatigue failure at this junction. Expert analysis of failed devices has identified consistent fracture patterns at or near the connector hub, suggesting a design-level problem rather than patient-specific factors.

FDA adverse event reports and regulatory history

The FDA's Manufacturer and User Facility Device Experience (MAUDE) database contains thousands of adverse event reports related to Bard PowerPort and similar implantable port devices. These reports document a consistent pattern of device failures including catheter fractures, migrations, infections, and thrombotic events spanning more than a decade. For attorneys, MAUDE reports provide a valuable source of evidence demonstrating that the manufacturer had notice of recurring device failures.

Bard PowerPort devices have been subject to multiple FDA recalls and safety communications. The FDA has classified these devices as Class II medical devices, which require a 510(k) premarket notification but not the more rigorous premarket approval (PMA) process reserved for Class III devices. Plaintiffs argue that the 510(k) pathway allowed Bard to bring the PowerPort to market without adequate testing.

Key regulatory milestones include multiple recall events for specific PowerPort lots due to manufacturing defects, FDA warning letters to Bard facilities regarding quality system violations, and post-market surveillance data indicating failure rates exceeding those predicted by the manufacturer. Attorneys should obtain complete FDA correspondence files through FOIA requests and leverage these documents to demonstrate that Bard was aware of systemic quality issues.

MDL status and litigation landscape

Bard PowerPort litigation has been consolidated for pretrial proceedings in multidistrict litigation (MDL). The Judicial Panel on Multidistrict Litigation (JPML) centralized these cases to promote efficient discovery, avoid duplicative rulings, and facilitate consistent case management. The MDL includes cases from across the country alleging similar product liability claims against C.R. Bard and Becton Dickinson.

Current MDL proceedings

The MDL court has established a leadership structure including lead counsel, a plaintiffs' steering committee, and specialized discovery committees. Bellwether cases have been selected to test the strength of various claim theories and factual scenarios before a jury. These bellwether trials are expected to provide crucial data points for potential global settlement negotiations.

State court actions

In addition to the federal MDL, some plaintiffs have filed Bard PowerPort cases in state courts. State court filings may be strategically advantageous in jurisdictions with favorable product liability law, shorter time to trial, or plaintiff-friendly jury pools. Attorneys should evaluate whether MDL participation or state court filing better serves each individual client's interests.

Legal theories in Bard PowerPort cases

Successful Bard PowerPort claims typically rely on multiple legal theories, each supported by distinct evidence and expert testimony. Attorneys should plead all viable theories to maximize recovery potential.

Qualifying criteria for Bard PowerPort claims

For attorneys evaluating potential Bard PowerPort cases, establishing qualification is the critical first step. The following criteria represent the core elements that most plaintiff firms and litigation funding partners use to assess case viability.

Device identification

The claimant must have had a Bard PowerPort device specifically — not a competing manufacturer's implantable port — implanted at some point. Device identification can be confirmed through operative reports, implant cards, hospital records, and device tracking databases. It is important to distinguish Bard PowerPort devices from ports manufactured by competitors such as AngioDynamics, Teleflex, or Cook Medical.

Documented complications

The claimant must have experienced one or more qualifying complications, including but not limited to catheter fracture or breakage, catheter migration (confirmed by imaging), device-related infection requiring treatment, deep vein thrombosis or pulmonary embolism, need for surgical device removal or revision, cardiac perforation or tamponade, or other serious complications requiring hospitalization.

Medical record documentation

Strong cases require medical records documenting both the device implantation and the subsequent complications. Imaging studies showing catheter fracture or migration, operative reports from device removal procedures, pathology reports from explanted devices, and records of emergency department visits or hospitalizations all provide critical evidentiary support.

Settlement data and case valuations

While the Bard PowerPort MDL has not yet produced a global settlement, individual case valuations and early settlement discussions provide useful benchmarks. Attorneys can look to prior medical device mass tort settlements for guidance — IVC filter litigation, which involved similar catheter migration and device failure issues, produced settlements and verdicts ranging from tens of thousands to several million dollars per case.

Building a strong Bard PowerPort case: evidence and discovery

Building a compelling Bard PowerPort case requires a systematic approach to evidence gathering that begins at intake and continues through discovery.

• Device preservation: Ensure explanted PowerPort devices are preserved for expert analysis. A biomedical engineer can identify the specific failure mode (fracture pattern, degradation evidence, manufacturing defects) and provide powerful demonstrative evidence for trial.
• Medical record acquisition: Obtain records from the implanting facility, the facility where complications were treated, all subsequent treating physicians, and imaging centers. Focus on operative notes, radiology reports, pathology reports, and discharge summaries.
• Expert retention: A biomedical engineer for device design defects, an interventional radiologist for clinical consequences, a hematologist or infectious disease specialist for thrombosis or sepsis, and an economist for future damages quantification.
• MAUDE database review: Obtain and analyze FDA adverse event reports demonstrating manufacturer notice of recurring device failures.
• FOIA requests: Obtain complete FDA correspondence files including recall events, warning letters, and post-market surveillance data.

The role of Becton Dickinson in Bard PowerPort litigation

In 2017, Becton, Dickinson and Company (BD) acquired C.R. Bard for approximately $24 billion, making BD one of the largest medical technology companies in the world. This acquisition is significant for litigation because BD assumed Bard's liabilities, including product liability claims related to the PowerPort.

BD's substantial financial resources and diverse product portfolio mean that the company has the capacity to fund significant litigation defense and, ultimately, to pay substantial settlements or judgments. BD's annual revenue exceeds $19 billion, and the company maintains insurance coverage and litigation reserves that provide a deep pool from which to satisfy product liability claims. The acquisition also raises questions about post-acquisition conduct — if BD continued to sell PowerPort devices despite knowledge of safety issues, plaintiffs may argue independent negligence by BD.

Preemption defense and why it fails in PowerPort cases

Defendants in medical device cases often assert federal preemption as a defense. However, the preemption defense is significantly weaker for devices cleared through the 510(k) pathway than for devices approved through PMA. The Supreme Court's decision in Medtronic v. Lohr (1996) held that the 510(k) process does not impose device-specific federal requirements that would preempt state law claims. Because the Bard PowerPort was cleared through 510(k), state law product liability claims are generally not preempted.

Cross-referencing related practice areas

Bard PowerPort cases are a natural fit for firms with medical device litigation experience. Firms active in this area may also benefit from diversifying into related mass tort practice areas like hernia mesh, hair relaxer cancer, or Ozempic gastroparesis claims, providing revenue stability and a broader client base.